Lucid Diagnostics Q2 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $1.474M Miss $1.943M Estimate
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 33.33 percent. This is a 20 percent increase over losses of $(0.10) per share from
Lucid Diagnostics lost more money per share than experts expected, and made less sales than hoped. When a company misses on both numbers, it hints things aren't going as well as people thought they would.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.